Summer 2025 Will Be 15 Minutes Shorter Than Last Year — Here's Why
Summer 2025 will be 15 minutes shorter than summer 2024.
Summer this year in the Northern Hemisphere summer will be shorter — by exactly 15 minutes — than it was in 2024 because, according to Timeanddate.com, of the ever-changing shape of Earth's orbit around the sun.
Earth currently orbits the sun along a slightly elliptical path, which makes summers in the Northern Hemisphere longer than those in the Southern Hemisphere — and they're getting longer each year. However, that pattern is interrupted this year. Here's everything you need to know about why.
Earth's Elliptical Orbit
At 15:54 EDT on Thursday, July 3, Earth will reach its farthest point from the sun for the entire year. Astronomers call this aphelion. On that date, Earth receives less radiation from the sun, which is at its smallest in the sky. Earth next reaches its perihelion — its closest point to the sun — at 12:15 p.m. EDT on Jan. 3, 2026. Earth will get maximum radiation from the sun, which will be at its largest in the sky on that day.
Crucially, none of this has anything to do with seasons on Earth, which is a result of the Earth's tilted axis. When the Northern Hemisphere is tilted toward the sun, it's summer, which is defined as between the solstice in June and the equinox in September.
Why Summer Lasts Longer North Of The Equator
Although it may not define the seasons, Earth's elliptical orbit around the sun does affect the duration of the seasons. At aphelion, Earth is farthest from the sun, so it takes a slightly longer path than when it's at perihelion when it moves slightly faster. Since aphelion occurs a couple of weeks after summer has begun in the Northern Hemisphere, aphelion makes summer last slightly longer than the Southern Hemisphere's summer (which occurs between the December solstice and the March equinox). As it stands, summer in the Northern Hemisphere is about four days longer than summer in the Southern Hemisphere, according to Timeanddate.com.
However, the gravitational influence of the sun, the moon and even Jupiter causes minute fluctuations in the shape and speed of Earth's orbit from year to year. In 2025, this will result in a slightly shorter summer than in 2024 — 93 days, 15 hours, and 37 minutes, down from 93 days, 15 hours, and 52 minutes. In 2026, summer will be three minutes longer than in 2025.
Wishing you clear skies and wide eyes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
40 minutes ago
- CNN
BMI is BAD, a new study suggests. Here's a better way to measure weight
Food & health WellnessFacebookTweetLink Follow When it comes to measuring weight, BMI is the acronym everyone loves to hate. Health professionals have long used body mass index as a quick screening tool to fast-track certain patients into a 'code red' management plan — people whose weight puts them in danger of future health problems. The issue is that BMI measures health risk by calculating height and weight. However, muscle and bone weigh more than fat, so BMI measurements can overestimate the danger for people with a muscular build or a larger frame. Conversely, BMI can underestimate health concerns in older adults and anyone who has lost muscle, according to the Harvard T.H. Chan School of Public Health in Boston. Now, authors of a new study say a different approach to weight measurement may be a more accurate way to predict future health issues. Bioelectrical impedance analysis, or BIA, uses undetectable electric currents to measure not only the percentage of body fat but also lean muscle mass and water weight. The technology works like this: You stand on metal plates on the machine while holding your hands or thumbs on another metal attachment held away from the body. Once started, the machine sends a weak electrical current through the body. Body fat, muscle and bone all have different electrical conductivity, so the machine uses algorithms to determine lean muscle mass, body fat percentage and water weight. 'We found body-fat percentage to be a stronger predictor of 15-year mortality risk in adults between the ages of 20 and 49 than BMI,' said Arch Mainous III, lead author of the study published Tuesday in the journal Annals of Family Medicine. When it came to deaths from heart disease, people with high body fat as measured by BIA were 262% times more likely to die than people who had a healthy percentage of body fat, said Mainous, a professor and vice chair of research in community health and family medicine at the University of Florida School of Medicine. 'Now remember, using BMI did not flag any risk at all in this younger population, which isn't one we typically consider to be at high risk for heart disease,' said senior author Dr. Frank Orlando, a clinical associate professor of community health and family medicine at University of Florida Health. 'Think of the interventions we can do to keep them healthy when we know this early. I think it's a game-changer for how we should look at body composition,' Orlando said. BMI is measured by dividing your weight by the square of your height. (If you are mathematically challenged like I am, the National Institutes of Health has a free calculator.) In BMI world, a body mass between 18.5 and 24.9 is a healthy weight, between 25 and 29.9 is overweight, between 30 and 34.9 is obese, between 35 and 39.9 is class 2 obesity, and anything greater than 40 is 'severe' or class 3 obesity. People are considered underweight if their BMI is lower than 18.5. Using BMI to measure health risk works — on a population level. Countless studies have shown that a greater BMI really does correlate with developing chronic diseases of all kinds — cancer, heart disease, type 2 diabetes, kidney and liver disease, and more. Where BMI fails is at the patient level. Imagine a patient who is 'skinny fat' — thin on the outside but riddled with globs of fat wrapped around major organs on the inside. Your BMI would be fine even though your health was at risk. 'Those people are more likely to have nonalcoholic fatty liver disease, more likely to have elevated glucose, more likely to have elevated blood pressure, and more likely to have inflammation in general,' Mainous said. All of these health issues can be treated, stopped and in some cases even reversed if caught early enough, he added. While doctors are aware of the issues with BMI, many prefer it 'because it is cheap and easily put into practice,' Mainous said. 'They'd like to use a more direct measurement such as a DEXA scan, but those cost too much and are not widely available, so everyone falls back to the indirect measure of BMI.' DEXA stands for dual-energy X-ray absorptiometry and is the gold standard for body mass analysis. Such machines can cost between $45,000 and $80,000, so patients typically travel to a hospital or specialty center to get the scan, Orlando said. The cost to the patient can easily be $400 to $500 per scan, he said. 'However, we found the newer versions of bioelectrical impedance are pretty accurate, giving some valid and reliable results,' Orlando said. One note — at-home based bioelectrical impedance products are not nearly as accurate, said Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver. 'They can be affected a lot by how much body fluid you have, how hydrated you are,' said Freeman, who was not involved with the new research. 'At-home measurements will only give a ballpark — the clinic-based machines are more precise.' The new study analyzed data on 4,252 men and women who participated in the 1999 to 2004 federal survey called NHANES, or the National Health and Nutrition Examination Survey, a yearly checkup of the nation's health. Technicians measured each person's body composition, including height, weight and waist circumference. In addition, all participants underwent a clinic-based bioelectrical impedance analysis, which measures the body's resistance to electrical currents. Researchers then compared that data with the National Death Index through 2019 to see how many people died. After adjusting for age, race and poverty status, the study found a BMI that labeled someone as obese was not associated with a statistically significant higher risk of death from any cause, when compared with those in healthy BMI range. People with high body fat as measured by bioimpedance analysis, however, were 78% more likely to die from any cause, Mainous said. Measuring waist circumference was also helpful, but not as accurate as body mass. Add that to the 262% higher chance of dying from heart disease found by the study, and it's a no-brainer for doctors to use bioelectrical impedance analysis on patients, Orlando said. 'Let's face it, the magnitude of risk this study shows is enormous,' Freeman said. 'It's scary to think that we may have been using a surrogate — BMI — that may not have been all that accurate over the years.' The study shows how better weight measurements could easily become personalized medicine, Freeman added. 'Imagine you came into your doctor's office,' he said. 'They provided your body fat percentage and an individualized risk assessment. They talked to you about exercise and other lifestyle changes and referred you to a nutritionist. 'They gave you an opportunity to make these changes, and then if needed, helped you out with medication. If the medical profession did this and were able to save many more lives, that would be amazing.' Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
Gizmodo
2 hours ago
- Gizmodo
Study Says U.S. Babies Are Missing a Key Gut Microbe, Fueling Allergy Risk
The prevalence of allergies and other chronic diseases is on the rise, with the number of food allergy cases in the U.S. increasing 50% between 2007 and 2021. These allergies can be life-threatening, and understanding their root cause is more important than ever before. A new study has brought experts closer to doing just that. The findings, published Tuesday, June 24 in the journal Communications Biology, linked the rise of allergies and other chronic conditions such as asthma and eczema to the disappearance of Bifidobacterium from babies' guts. These bacteria play a crucial role in breaking down breast milk, particularly complex sugars called human milk oligosaccharides (HMOs). A century ago, they were abundant in the microbiomes of breastfed infants, but their prevalence has dwindled among babies in industrialized nations. Initial results from the My Baby Biome study—a large-scale investigation of infant gut microbiomes in the U.S.—found that roughly 25% of infants lack detectable Bifidobacteria. The researchers suggest this increases their risk of developing noncommunicable diseases. 'It's in this population where we have low Bifidobacteria or altered Bifidobacteria that we see a very significant increase in risk for non-communicable disease conditions, or atopic disease conditions such as food allergies, eczema, atopic dermatitis and asthma,' said co-author Stephanie Culler, CEO and co-founder of Persephone Biosciences—the San Diego-based biotech company that created the My Baby Biome study. According to the company, My Baby Biome is one of the largest and most comprehensive investigations of infant guts in the U.S. to date. This longitudinal study aims to monitor the gut microbiomes and health outcomes of hundreds of infants over seven years. The findings published Tuesday come from the study's first two years, during which researchers collected and analyzed stool samples from 412 infants aged four weeks to 12 weeks who were 'representative of U.S. demographic diversity.' The researchers found that 76% of U.S. infant guts had deficient levels of Bifidobacteria, and 25% had no detectable Bifidobacteria. These bacteria play a critical role in infant health and development, particularly when it comes to protecting babies from chronic illness. Multiple studies suggest Bifidobacterium has been disappearing from infant microbiomes for decades largely due to dietary changes, cesarean sections, antibiotic use, and sanitation. This trend coincides with a rise in noncommunicable diseases, according to the researchers. The fact that a quarter of the infants showed a total lack of Bifidobacterium may sound staggering, but Jack Gilbert, a professor of pediatrics at the University of California San Diego, was actually surprised by how low that number was. Some previous estimates suggest that 50% to 60% of U.S. infants lack one type of Bifidobacterium called B. longum infantis, he told Gizmodo in an email. This subspecies is known for its ability to digest HMOs. From the 412 participants, the researchers received 210 follow-up health surveys at two years of age. Among these babies, 30% had an adverse health outcome, with 12.4% reporting allergies, 21.0% reporting eczema or dermatitis, and 3.3% reporting asthma. Statistical analysis revealed that babies with deficient levels or a total lack of Bifidobacteria—who made up 76% of the participants—were at greater risk of developing chronic immune conditions. What's more, the researchers found thatinfant Bifidobacterium has a protective effect, reducing relative risk in the population. This isn't the first study to link deficient infant Bifidobacterium to increased risk of chronic immune conditions, Gilbert said. Previous studies have shown that when these bacteria digest HMOs, they shape gut microbiome dynamics that help train immune system responses, he explained. Additionally, nutrients produced by the breakdown of breast milk sugars support the development of endocrine, neurological, and immunological cells that prevent the immune system from attacking healthy cells, he added. Investigating the role that infant microbiomes play in the rise of noncommunicable diseases 'is central to the health of our population,' Gilbert said. Culler agrees. Over the next several years of the My Baby Biome study, she and her colleagues will work to understand the health outcomes that arise from Bifidobacteria-deficiencies over time, probing their impact on neurological disorders, obesity, and even diabetes risk. Unlocking the microbial mechanisms behind these conditions could lay the groundwork for better interventions, she said.
Associated Press
2 hours ago
- Associated Press
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
Watertown, MA June 24, 2025 --( )-- The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. This milestone is made possible through a new supply agreement with Axol Bioscience Ltd., a leading provider of iPSC-derived cells and services. These iPSC lines, developed by ALS TDI from samples generously donated by participants in the ALS Research Collaborative (ARC) Study, represent both genetic and sporadic forms of ALS. They include key ALS-associated mutations such as C9orf72, SOD1, and TDP-43, and will be used to generate ALS-relevant cell types—including motor neurons, microglia, and astrocytes—for use in drug discovery and disease modeling. The goal of this collaboration is to provide high-quality research tools to the global scientific community, including academic and pharmaceutical researchers, to help further the understanding and development of treatments for ALS. 'This is a major step forward for ALS research,' said Dr. Fernando Vieira, CEO and Chief Scientific Officer at ALS TDI. 'By making these iPSC-derived cells broadly accessible through Axol's infrastructure, we are ensuring that the contributions of people with ALS who shared their samples and data through ARC can drive discoveries in labs across the globe.' ALS TDI has built one of the most comprehensive collections of ALS-specific iPSCs available today. These cells are derived from real people living with ALS, many of whom also shared clinical data, creating a uniquely valuable resource for understanding disease mechanisms and testing potential treatments. Through this agreement, Axol will manufacture and distribute iPSC-derived cells to academic and industry researchers worldwide, ensuring quality, consistency, and scalability. The goal, to accelerate progress across the ALS field by providing powerful, human-relevant tools that better reflect the diversity and complexity of the disease. 'Collaborating with ALS-TDI allows us to broaden access to highly disease-relevant iPSC models of ALS, which are vital for understanding disease mechanisms and accelerating therapeutic discovery for patients and their families,' said Liam Taylor, CEO of Axol Bioscience. 'This partnership aligns with our mission to build and enable better human disease models by providing high-quality, human-relevant cells and models that advance neuroscience research and drug development.' ALS TDI extends its deepest thanks to every person living with ALS who contributed to this effort. Their willingness to share samples and data through the ARC Study has made this breakthrough possible. To learn more about the ALS Research Collaborative, visit For more information, please contact: Axol Bioscience Duncan Borthwick [email protected] ALS Therapy Development Institute Fernando Vieira [email protected] About Axol Bioscience Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. Axol has a deep connection with the ALS research community and works to support the creation of more human relevant in vitro models to accelerate discovery and therapeutic development. About ALS Therapy Development Institute (ALS TDI) The ALS Therapy Development Institute (ALS TDI) is the world's first and largest nonprofit biotech dedicated solely to discovering and developing effective treatments for ALS. Based in Watertown, Massachusetts, ALS TDI runs a state-of-the-art research center and leads the ALS Research Collaborative (ARC)—one of the most comprehensive and longest-running natural history studies in ALS. Through innovative, patient-driven science, ALS TDI is working to end ALS for everyone affected by this devastating disease. Contact Information: ALS Therapy Development Institute Meghan Lawlor (978)729-2961 Contact via Email Read the full story here: ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research Press Release Distributed by
